Daily Medication Pearl: Ocrelizumab (Ocrevus) for Multiple Sclerosis

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

Medication Pearl of the Day: Ocrelizumab (Ocrevus)

Indication: Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

Insight:

  • Dosing: Administer Ocrelizumab by intravenous (IV) infusion. Start dose 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion. Subsequent doses: 600 mg IV infusion every 6 months.
  • Dosage form: Injection 300 mg/10 mL (30 mg/mL) in a single-dose vial.
  • Adverse events (AEs): The most common AEs were upper respiratory tract infections and infusion reactions, skin infections, and lower respiratory tract infections.
  • Mechanism of action: Ocrelizumab is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
  • Manufacturer: Genentech

Sources: